This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Bank of America, Abbott Laboratories, Chevron, Danaher and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Abbott Laboratories, Chevron, Danaher and GlaxoSmithKline
Top Stock Reports for Bank of America, Abbott & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Abbott Laboratories (ABT) and Chevron (CVX).
Logitech (LOGI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
A strong Video Collaboration business is expected to have driven Logitech's (LOGI) first-quarter fiscal 2021 results. However, weak Mobile Speakers segment is likely to have remained an overhang.
Abbott (ABT) Q2 Earnings Top, Coronavirus Test Sales Solid
by Zacks Equity Research
Abbott (ABT) Q2 earnings reflect healthy growth within its Diabetes Care business and encouraging coronavirus test sales.
Abbott (ABT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 32.56% and 7.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
5 Earnings Charts for the Coronavirus Recovery
by Tracey Ryniec
Drug makers, restaurants, industrials and transports will tell you what is really going on in the US economy.
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The rest of businesses within Life-Science Solutions segment of Thermo Fisher (TMO) are likely to have registered strong quarterly growth led by genetic sciences and bio production businesses.
OrganiGram (OGI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and product launches in the fiscal third quarter despite pandemic-hit business conditions.
Why Earnings Season Could Be Great for Abbott (ABT)
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Aphria (APHA) Looks Good: Stock Adds 8.8% in Session
by Zacks Equity Research
Aphria (APHA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
What's in Store for Taiwan Semiconductor's (TSM) Q2 Earnings?
by Zacks Equity Research
Taiwan Semiconductor's (TSM) second-quarter results are likely to reflect robust technology portfolio and 5G deployment amid coronavirus pandemic.
The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing
Infosys (INFY) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
While Infosys' (INFY) Q1 performance is likely to have benefited from the ongoing digital transformations and large deal wins, elevated expenses might have hurt the bottom line.
Top Analyst Reports for Oracle, Abbott & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Abbott Laboratories (ABT) and Chevron (CVX).
Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes
by Zacks Equity Research
Bio-Rad (BIO) rides on the FDA's emergency use authorization EUA for the Droplet Digital PCR COVID-19 test kit.
LabCorp Launches At-Home Coronavirus Test Collection Kit
by Zacks Equity Research
LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.
Danaher Shares Gain 26% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Danaher (DHR), with 26% growth in shares in the past three months, benefits from healthy demand for its products and synergistic benefits from acquired assets despite the pandemic-led woes.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Zoom Video Communications, Amazon.com and NVIDIA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Zoom Video Communications, Amazon.com and NVIDIA
4 Stocks to Play the Alarming Spike in Cases of COVID-19
by Tirthankar Chakraborty
From an investment perspective, the spurt in new coronavirus cases over the July fourth weekend bodes well for certain stocks.
Medical Products Industry's Near-Term Outlook Lacks Spark
by Trina Mukherjee
AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $92.23, moving +0.64% from the previous trading session.
3 MedTech Stocks to Buy Amid Intensifying Coronavirus Fears
by Trina Mukherjee
Let's keep a watch on three stocks that have shown tremendous promise amid the pandemic.
Abbott, Tandem Diabetes Seal Deal on Diabetes Management
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.